An Interesting New Clinical Study: VIAging Deceleration Trial Using Metformin, Dasatinib, Rapamycin and Nutritional Supplements

#1

Brief Summary:

This study aims to assess the safety and efficacy of study drugs and supplements on clinical (structural and functional) signs of aging and to explore/identify other possible biological measures of aging.

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study to Test the Safety and Efficacy of Metformin, Dasatinib, Rapamycin and Nutritional Supplements (Bio-quercetin; Bio-fisetin; Glucosamine; Nicotinamide Riboside; Trans-resveratrol) in Reducing Clinical Measures of Aging in Older Adults
Estimated Study Start Date : December 2021
Estimated Primary Completion Date : August 2023
Estimated Study Completion Date : August 2023

Drug: Study Drugs and Nutritional Supplements

Step 1: 500 mg of metformin and increase their dose 500 mg every 2 weeks up to 2000 mg or until tolerable.

Step 2: Once at tolerable daily metformin dose, subjects will take 140 mg of dasatinib along with 58 mg to 174 mg (based on body weight) bio-quercetin and 44.5 mg bio-fisetin. Subjects will take dasatinib, bio-quercetin and bio-fisetin for 2 consecutive days as described 4 times over one year (every 3 months) while participating on this study.

Step 3: Two weeks after the first dasatinib dose is complete, subjects will start taking daily nutritional supplements of 1,500 mg glucosamine, 600 mg nicotinamide riboside and 500 mg trans-resveratrol.

Step 4: Two weeks after starting daily supplements in Step 3, subjects will take a once weekly 6 mg dose of rapamycin.

Once subject is taking rapamycin, they will continue on this intervention for 12 months.

Other Name: metformin, dasatinib, rapamycin and nutritional supplements (bio-quercetin; bio-fisetin; glucosamine; nicotinamide riboside; trans-resveratrol)

4 Likes
#3

Maybe the plan is to assess safety, look at various markers and then use that to narrow the scope of the next study, which would presumably be double blind, placebo-controlled and have a much smaller number of interventions.

1 Like
#4

The study was withdrawn. Any way to see why? I find the format very hard to make sense of in terms of updates.

#5

You could try calling them…

Overview

Vitality in Aging Research Group, Inc. (VIAging) is a non-profit organization dedicated to investigating the health, well-being, and aging of older adults and the factors that may contribute to and accelerate the aging process. One of the leading causes of death is aging and age-related diseases such as heart failure, dementia, atrial fibrillation, fractures due to osteoporosis, pneumonia due to a declining immune system, just to name a few. Yet, many of the risk factors contributing to aging are poorly understood. VIAging’s mission is to better understand what drives aging and by doing so discover the mechanisms that may allow humans to slow or even reverse the processes of aging. By identifying biological markers of aging and healthy lifestyle traits, researchers may be able to identify effective strategies and possible interventions to reduce age-related diseases and conditions which contribute to aging and may ultimately cause death.

Website
https://vitalityinaging.org
Phone
Phone number is 561-203-5761

Industry
Research Services

Company size
2-10 employees

#6

The only piece of info I’m really interested in is whether they pulled the plug early due to adverse effects. The juice may not be worth the squeeze for calling them up. It seemed pretty aggressive anyway and I’m young and not in the market currently for such an intervention. But I was curious to see how it would fare.